Hemodialysis patients. Chronic renal failure
Conditions
Interventions
Intervention 1: Intervention: Carnitine (1000mg iv, 3x/week). Intervention 2: Intervention: Ubiquinone (100mg/day, oral). Intervention 3: Intervention: Carnitine (1000mg iv, 3x/week) and ubiquinone (1
Treatment - Drugs
Placebo
Intervention: Carnitine (1000mg iv, 3x/week)
Intervention: Ubiquinone (100mg/day, oral)
Intervention: Carnitine (1000mg iv, 3x/week) and ubiquinone (100mg/day, oral)
Control: saline (5cc iv, 3x/week) and lactose (100mg/d, oral)
Sponsors
Vice Chancellor for Research, Tehran University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Patients under hemodialysis for at least one yer; 2. Serum levels of Lp(a) >20 mg/dl and homocysteine =>15 mg/dl; 3. Willingness to participate and filling up the consent form. Exclusion criteria: 1. Patients with acute or chronic infection; 2. Patients taking carnitine, ubiquinone, vitamins A,E and C during the last month prior to the trial.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardio-vascular risk factors. Timepoint: Before and after 3 months after intervention. Method of measurement: Serum levels of Lp(a) (Elisa); homocysteine (Enzymatic cycling); and malondialdehyde (spectophotometry). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mir-Hatef Shojaei
School of Public Health; Tehran University of Medical Sciences and Health Services (TUMS)
Outcome results
None listed